Ecolab Inc. (NYSE:ECL – Get Free Report) major shareholder William H. Gates III sold 409,136 shares of Ecolab stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $246.92, for a total transaction of $101,023,861.12. Following the sale, the insider now directly owns 30,776,418 shares of the company’s stock, valued at $7,599,313,132.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Ecolab Price Performance
Shares of Ecolab stock traded down $0.07 during trading on Monday, reaching $244.50. 1,008,311 shares of the company’s stock were exchanged, compared to its average volume of 1,089,320. The firm’s 50-day moving average price is $252.59 and its 200 day moving average price is $242.28. The company has a market cap of $69.57 billion, a P/E ratio of 34.29, a PEG ratio of 2.49 and a beta of 1.13. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.10 and a current ratio of 1.30. Ecolab Inc. has a 1-year low of $172.79 and a 1-year high of $262.61.
Ecolab (NYSE:ECL – Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The basic materials company reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.82 by $0.01. Ecolab had a net margin of 13.05% and a return on equity of 22.12%. The business had revenue of $4 billion during the quarter, compared to analysts’ expectations of $4.03 billion. During the same period in the prior year, the company earned $1.54 EPS. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. As a group, research analysts anticipate that Ecolab Inc. will post 6.66 earnings per share for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on ECL
Hedge Funds Weigh In On Ecolab
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Catalytic Wealth RIA LLC grew its holdings in Ecolab by 187.4% during the 3rd quarter. Catalytic Wealth RIA LLC now owns 2,454 shares of the basic materials company’s stock worth $627,000 after acquiring an additional 1,600 shares during the period. Wolverine Asset Management LLC bought a new position in Ecolab during the third quarter worth $1,404,000. Kennebec Savings Bank acquired a new stake in Ecolab in the third quarter worth $628,000. Arvest Investments Inc. raised its holdings in shares of Ecolab by 1.1% during the third quarter. Arvest Investments Inc. now owns 3,950 shares of the basic materials company’s stock valued at $1,009,000 after purchasing an additional 44 shares during the period. Finally, Eagle Bluffs Wealth Management LLC grew its stake in shares of Ecolab by 1.0% in the 3rd quarter. Eagle Bluffs Wealth Management LLC now owns 4,724 shares of the basic materials company’s stock valued at $1,209,000 after buying an additional 45 shares during the period. Institutional investors and hedge funds own 74.91% of the company’s stock.
About Ecolab
Ecolab Inc provides water, hygiene, and infection prevention solutions and services in the United States and internationally. The company operates through three segments: Global Industrial; Global Institutional & Specialty; and Global Healthcare & Life Sciences. The Global Industrial segment offers water treatment and process applications, and cleaning and sanitizing solutions to manufacturing, food and beverage processing, transportation, chemical, metals and mining, power generation, pulp and paper, commercial laundry, petroleum, refining, and petrochemical industries.
Further Reading
- Five stocks we like better than Ecolab
- What is Put Option Volume?
- Intel: Is Now the Time to Be Brave?Â
- Learn Technical Analysis Skills to Master the Stock Market
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- 5 Top Rated Dividend Stocks to Consider
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Ecolab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ecolab and related companies with MarketBeat.com's FREE daily email newsletter.